Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Amounts reported in the unaudited condensed consolidated balance sheet as of 31 March, 2019 were (in thousands):


		March 31,
		2019
Operating lease right of use assets	$	24,462
Operating lease liabilities, current		(2,217)
Operating lease liabilities, non-current		(26,779)
Total operating lease liabilities	$	(4,534)

The maturities of operating lease liabilities are as follows (in thousands):


	Operating leases

2019	$	2,465
2020		4,136
2021		4,172
2022		4,216
2023		3,936
after 2023		16,520
Total lease payments		35,445
Less: Imputed interest		6,449
Present value of lease liability	$	28,996


	Amount reclassified
	Three months ended		Three months ended
	March 31,		March 31,
Component of Accumulated Other Comprehensive Income	2019		2018

Unrealized gains (losses) on available-for-sale securities
Reclassification adjustment for losses on available-for-sale debt securities	$	—	$	1,163